C. F. O'Brien

1.4k total citations
10 papers, 1.1k citations indexed

About

C. F. O'Brien is a scholar working on Neurology, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, C. F. O'Brien has authored 10 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Neurology, 4 papers in Cellular and Molecular Neuroscience and 2 papers in Pharmacology. Recurrent topics in C. F. O'Brien's work include Neurological disorders and treatments (6 papers), Botulinum Toxin and Related Neurological Disorders (4 papers) and Parkinson's Disease Mechanisms and Treatments (3 papers). C. F. O'Brien is often cited by papers focused on Neurological disorders and treatments (6 papers), Botulinum Toxin and Related Neurological Disorders (4 papers) and Parkinson's Disease Mechanisms and Treatments (3 papers). C. F. O'Brien collaborates with scholars based in United States and India. C. F. O'Brien's co-authors include J. Timothy Greenamyre, John Mark S. de Leon, John Gibson, Michele Tagliati, Edward P. Monaghan, David M. Simpson, David N. Alexander, Michael L. Perlis, John P. Hammerstad and Yinglin Xia and has published in prestigious journals such as Neurology, Movement Disorders and Sleep Medicine.

In The Last Decade

C. F. O'Brien

10 papers receiving 1.1k citations

Peers

Countries citing papers authored by C. F. O'Brien

Since Specialization

Citations

This map shows the geographic impact of C. F. O'Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. F. O'Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. F. O'Brien more than expected).

Fields of papers citing papers by C. F. O'Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. F. O'Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. F. O'Brien. The network helps show where C. F. O'Brien may publish in the future.

Co-authorship network of co-authors of C. F. O'Brien

This figure shows the co-authorship network connecting the top 25 collaborators of C. F. O'Brien. A scholar is included among the top collaborators of C. F. O'Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. F. O'Brien. C. F. O'Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study 2013 ·Reproductive Sciences ·Michael P. Diamond, Bruce R. Carr, W. Paul Dmowski, William Koltun, C. F. O'Brien, Ping Jiang, Joshua Burke, Roland Jimenez, Elizabeth Garner, Kristof Chwalisż	89
2	The efficacy of cognitive-behavioral therapy for insomnia in patients with chronic pain 2010 ·Sleep Medicine ·Carla R. Jungquist, C. F. O'Brien, Sara Matteson-Rusby, Michael T. Smith, Wilfred R. Pigeon, Yinglin Xia, Naiji Lu, Michael L. Perlis	186
3	The clinical profile of elan pharmaceuticals' botulinum toxin type B 2001 ·European Journal of Neurology ·C. F. O'Brien	4
4	Chemodenervation with botulinum toxin for spasticity and dystonia. The effects on gait. 2001 ·PubMed ·C. F. O'Brien	3
5	Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients. 1998 ·PubMed ·Paul A. Cullis, C. F. O'Brien, Daniel Truong, M. Köller, (unknown), J D Wallace	17
6	A controlled trial of fluoxetine in nondepressed patients with Huntington's disease 1997 ·Movement Disorders ·Peter G. Como, Allen Rubin, C. F. O'Brien, Kathy Lawler, Charlyne Hickey, (unknown), (unknown), Michael McDermott, (unknown), (unknown), Ira Shoulson	61
7	Ropinirole for the treatment of early Parkinson's disease 1997 ·Neurology ·Charles H. Adler, Kapil D. Sethi, Robert A. Hauser, Thomas L. Davis, John P. Hammerstad, John M. Bertoni, R. L. Taylor, Juan Sanchez‐Ramos, C. F. O'Brien, (unknown)	225
8	Botulinum toxin type A in the treatment of upper extremity spasticity 1996 ·Neurology ·David M. Simpson, David N. Alexander, C. F. O'Brien, Michele Tagliati, (unknown), John Mark S. de Leon, John Gibson, (unknown), Edward P. Monaghan	336
9	Lack of a detectable systemic humoral/cellular allogeneic response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson's disease. 1995 ·PubMed ·Aftab A. Ansari, Ann E. Mayne, Curt R. Freed, Robert E. Breeze, Stuart A. Schneck, C. F. O'Brien, (unknown), (unknown), J.C. Mazziotta, Mark R. Hutchinson	11
10	N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's Disease 1991 ·Archives of Neurology ·J. Timothy Greenamyre, C. F. O'Brien	186

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact